Extent of apoptosis in relation to p53 and bcl-2 expression in germ cell tumors

Human Pathology

Volumn 27, Issue 11, 1996, Pages 1221-1226

  Soini, Ylermi ^a   Pääkkö, Paavo ^a  

^a UNIVERSITY OF OULU   (Finland)

Author keywords

apoptosis; bcl 2; germ cell tumor; p53

Indexed keywords

PROTEIN BCL 2; PROTEIN P53;

APOPTOSIS; ARTICLE; CHORIOCARCINOMA; EMBRYONAL CARCINOMA; FEMALE; GERM CELL TUMOR; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; ONCOGENE; TERATOMA; TUMOR SUPPRESSOR GENE;

EID: 0029854194     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0046-8177(96)90318-4     Document Type: Article

References (18)

1. Hockenbery DM: Bcl-2 in cancer, development and apoptosis. J Cell Sci 18:51-55, 1994
2. Kerr JFR, Winterford CM, Harmon BV: Apoptosis. Its significance in cancer and cancer therapy. Cancer 73:2013-2026, 1994
3. Reed JC: Bcl-2 and the regulation of programmed cell death. J Cell Biol 124:1-6, 1994
4. Törmänen U, Eerola A-K, Rainio P, et al: Enhanced apoptosis predicts shortened survival in non-small cell lung carcinoma. Cancer Res 55:5595-5602, 1995
5. Soini Y, Virkajärvi N, Lehto V-P, et al: Hepatocellular carcinomas with a high proliferation index and a low degree of apoptosis and necrosis are associated with a shortened survival. Br J Cancer 73:1025-1030, 1996
6. Miyashita T, Reed JC: Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80:293-299, 1995
7. Yin X-M, Oltvai ZN, Korsmeyer SJ: BH1 and BH2 domains of bcl-2 are required for inhibition of apoptosis and heterodimerization with bax. Nature 369:321-323, 1994
8. Yonish-Rouach E, Resnitzky D, Lotem J, et al: Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 352:345-347, 1991
9. Murphy WM: Urological Pathology. Philadelphia, PA, Saunders, 1989, pp 314-379
10. Mostofi FK, Sobin L: Histological typing of testicular tumours. International Histological Classification of Tumours, vol 16. World Health Organization, Geneva, 1977
11. Serov SF, Scully RE, Sobin LH: Histological typing of Ovarian Tumours. International Histological Classification of Tumours, (no 9): Geneva, World Health Organization, 1973
12. Soini Y, Pääkkö P, Nuorva K, et al: Comparative analysis of p53 protein immunoreactivity in prostatic, lung and breast carcinomas. Virchows Arch A 421:223-228, 1992
13. Bodner SM, Minna JD, Jensen SM, et al: Expression of mutant p53 protein in lung cancer correlates with the class of p53 mutation. Oncogene 7:743-749, 1992
14. Bartkova J, Bartek J, Lukas J, et al: p53 protein alterations in human testicular cancer including pre-invasive intratubular germcell neoplasia. Int J Cancer 49:196-202, 1991
15. Lewis DJ, Sesterhenn IA, McCarthy WF, et al: Immunohistochemical expression of p53 tumor suppressor gene protein in adult germ cell testis tumors: Clinical correlation in stage I disease. J Urol 152:418-423, 1994
16. Peng H-Q, Hogg D, Malkin D, et al: Mutations of the p53 gene do not occur in testis cancer. Cancer Res 53:3574-3578, 1995
17. Hockenbery D, Nunez G, Milliman C, et al: Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348:334-336, 1990
18. Kamada S, Shimono A, Shinto Y, et al: Bcl-2 deficiency in mice leads to pleiotropic abnormalities: Accelerated lymphoid cell death in thymus and spleen, polycystic kidney, hair hypopigmentation, and distorted small intestine. Cancer Res 55:354-359, 1995